D Bernardeschi1,2,3, N Pyatigorskaya2,4, F Y Russo1,2,3, D De Seta1,2,3, G Corallo5, E Ferrary1,2,3, Y Nguyen1,2,3, O Sterkers1,2,3. 1. Département d'Otologie, Implants auditifs et Chirurgie de la base du crâne, Groupe hospitalier Pitié-Salpêtrière, Service d'Oto-Rhino-Laryngologie, AP-HP, Paris, France. 2. Sorbonne Universités, UPMC Univ Paris 06, Paris, France. 3. Réhabilitation chirurgicale mini-invasive et robotisée de l'audition, Inserm UMR-S 1159, Paris, France. 4. Groupe hospitalier Pitié-Salpêtrière, Service de neuroradiolgie, AP-HP, Paris, France. 5. Department of Otolaryngology, University of Siena, Siena, Italy.
Abstract
OBJECTIVE: To analyse the anatomical, functional and quality-of-life results when using bioactive glass in mastoid and epitympanic obliteration. DESIGN: Prospective clinical study. SETTING: Tertiary referral centre. PARTICIPANTS: Forty-one cases (39 patients) operated between May 2013 and January 2015. MAIN OUTCOME MEASURES: Anatomical results were evaluated by otomicroscopy 1 year after surgery and using imaging to detect residual disease. Functional results were studied by postoperative hearing gain. Quality of life was assessed with the Glasgow Benefit Inventory questionnaire and the success of surgery by a surgery-specific questionnaire. RESULTS: At 1 year, all patients presented a well-healed external auditory canal, with an intact tympanic membrane. In cases with cholesteatoma (n = 23), no recurrent retraction pockets or residual disease were observed on imaging studies. The overall air-bone gap closure was 7.7 ± 1.84 dB (mean ± se of the mean, P < 0.001, paired t-test). No significant differences were found on hearing results when comparing primary versus revision surgery, canal-wall-up versus canal-wall-down obliterations, type of tympanoplasty and presence of cholesteatoma (multifactor anova). The Glasgow Benefit Inventory improved with an average score of 28 and the success of surgery questionnaire showed a significant improvement in ear discharge and a moderate improvement in hearing and equilibrium. CONCLUSIONS: The use of bioactive glass for mastoid and epitympanic obliteration in canal-wall-down or canal-wall-up tympanoplasties is an effective procedure in both primary and revision surgery. The anatomical and functional results appear to be well correlated with patient experience and to the improvement in quality of life.
OBJECTIVE: To analyse the anatomical, functional and quality-of-life results when using bioactive glass in mastoid and epitympanic obliteration. DESIGN: Prospective clinical study. SETTING: Tertiary referral centre. PARTICIPANTS: Forty-one cases (39 patients) operated between May 2013 and January 2015. MAIN OUTCOME MEASURES: Anatomical results were evaluated by otomicroscopy 1 year after surgery and using imaging to detect residual disease. Functional results were studied by postoperative hearing gain. Quality of life was assessed with the Glasgow Benefit Inventory questionnaire and the success of surgery by a surgery-specific questionnaire. RESULTS: At 1 year, all patients presented a well-healed external auditory canal, with an intact tympanic membrane. In cases with cholesteatoma (n = 23), no recurrent retraction pockets or residual disease were observed on imaging studies. The overall air-bone gap closure was 7.7 ± 1.84 dB (mean ± se of the mean, P < 0.001, paired t-test). No significant differences were found on hearing results when comparing primary versus revision surgery, canal-wall-up versus canal-wall-down obliterations, type of tympanoplasty and presence of cholesteatoma (multifactor anova). The Glasgow Benefit Inventory improved with an average score of 28 and the success of surgery questionnaire showed a significant improvement in ear discharge and a moderate improvement in hearing and equilibrium. CONCLUSIONS: The use of bioactive glass for mastoid and epitympanic obliteration in canal-wall-down or canal-wall-up tympanoplasties is an effective procedure in both primary and revision surgery. The anatomical and functional results appear to be well correlated with patient experience and to the improvement in quality of life.
Authors: Victor J Kroon; Steven W Mes; Pepijn A Borggreven; Rick van de Langenberg; David R Colnot; Jasper J Quak Journal: Eur Arch Otorhinolaryngol Date: 2022-10-08 Impact factor: 3.236
Authors: G Lahlou; G Sonji; D De Seta; I Mosnier; F Y Russo; O Sterkers; D Bernardeschi Journal: Acta Otorhinolaryngol Ital Date: 2018-08 Impact factor: 2.124